Trazodone for Dogs: What the Evidence Actually Shows

Trazodone was never designed for dogs. It reached the human market in 1981 as an antidepressant, and it arrives in veterinary clinics in people-sized tablets — 50, 100, 150, 300 milligrams — which then have to be halved, quartered or sent to a compounding pharmacy for a nine-kilogram terrier. Nobody mentions that at the counter. Most of those tablets end up folded into a piece of cheese.

It is also, by a wide margin, the most-prescribed behavioural medicine in the dog population anyone has actually counted. Researchers who analysed more than 32 million canine records from a nationwide network of US primary-care hospitals found that 1.33 per cent of dogs were prescribed trazodone across 2010 to 2020. Fluoxetine, the drug most owners have heard of, sat at 0.02 per cent. Prescribing started around 2013 and climbed sharply after 2015.

That gap between volume and certainty is the story. The evidence behind trazodone isn't absent, but it is thinner, smaller and messier than the size of the prescription pile suggests — and almost nobody explains that to the person holding the tablet.

How an antidepressant for people became a dog medicine

Trazodone belongs to a class with a clumsy name: serotonin antagonist and reuptake inhibitor, or SARI. Translation: it parks itself on some of serotonin's receptors and blocks them, and at higher doses it slows the transporter protein that hauls serotonin back into nerve cells, leaving more of the chemical sitting in the gap between neurons.

What it does depends on how much you give. At low to moderate doses it blocks the serotonin 2A receptor, the histamine 1 receptor and the alpha-1 adrenergic receptor — which is where the heaviness, the drowsiness and a mild dip in blood pressure come from. Push the dose higher and it starts inhibiting the serotonin transporter, known as SERT, and touches a longer list of receptors (5-HT2C, 5-HT1D, 5-HT7, 5-HT1A, alpha-2) that are thought to produce the actual anti-anxiety effect. In humans, the antidepressant dose is roughly ten to fifty times the dose that blocks serotonin 2A. No one has produced the equivalent number for dogs.

So at the doses most dogs receive, you are mostly buying sedation with some anxiolytic spillover, not a treatment aimed at the anxiety itself. That distinction matters, because a dog that is too wobbly to panic is not the same as a dog that is no longer afraid.

There's a second wrinkle. Trazodone is broken down in the liver into meta-chlorophenylpiperazine, mercifully shortened to mCPP, which is itself a serotonin agonist. In people, roughly a fifth of the parent drug takes that route, and mCPP has been linked to panic, anxiety and dysphoria. Dog-specific metabolism data are scarce, and anecdotal reports describe dogs becoming more agitated rather than less on high doses. A drug that can generate its own anxiogenic metabolite is a drug worth titrating slowly.

What the trials measured, and what they quietly didn't

The strongest ground for trazodone in dogs is not what most people assume. It isn't separation anxiety or thunderstorm phobia — those indications rest largely on clinical experience and small case series. It's the short, sharp, predictable stressor: the vet visit, the hospital stay, the weeks of crate rest after orthopaedic surgery.

At the University of California, Davis, researchers ran a randomised, double-blind, placebo-controlled crossover trial in 20 dogs with a history of anxiety at the vet. Each dog got a single dose of trazodone at 9 to 12 mg/kg, or a placebo, 90 minutes before transport to the clinic. On trazodone, owner-rated stress scores fell, dogs spent less time showing stress behaviour on video in the exam room, and respiratory rate dropped. Serum cortisol — the adrenal hormone you'd expect to fall if the animal were genuinely less frightened — did not change meaningfully. Behaviour improved. The physiology underneath it did not entirely follow.

For hospitalised dogs, a 2016 study found trazodone reduced several observed stress behaviours compared with an environment-matched control group. In the 2021 review in the Canadian Veterinary Journal that gathered this literature together, that study was the best-designed of the three it assessed, though still confounded by other medications and the absence of a true control. The same review lists the post-surgical confinement evidence in its dosing table with two blunt words: no effect.

That third row is the one to read twice. The open-label trial of 36 dogs recovering from orthopaedic surgery looked like a triumph: 89 per cent of owners said their dog improved. Then the same research group ran a placebo-controlled version with 29 dogs — 14 on trazodone, 15 on placebo — and found no difference between the groups. More than 70 per cent of owners in both arms described their dog's pill as moderately or extremely helpful.

This is the placebo-by-proxy problem in one tidy number. An owner who has paid for a drug, worried about the surgery and watched their dog like a hawk will tend to see improvement. The full review, available in the open-access text of the Canadian Veterinary Journal review, is candid about how much of the confidence in trazodone rests on designs like these.

An evidence appraisal published in Veterinary Evidence rated the overall support for trazodone in hospitalised and post-surgical dogs as weak, and noted that a properly powered trial would need something like 323 dogs. The published studies enrolled 36, 29 and 20.

Photo by Amrit Das on Unsplash

The ninety-minute rule, and why timing beats dose

Ask a vet when to give trazodone and you'll usually hear: about 90 minutes before the thing. That figure isn't folklore. In the post-operative study, owners reported a median onset of 31 to 45 minutes, with most noticing an effect somewhere between 16 and 90 minutes, and a median duration of four hours or more.

The trouble is underneath the average. In a pharmacokinetic study of six beagles given 8 mg/kg orally, the time to peak plasma concentration averaged 445 minutes with a spread of 271 minutes either side. One dog peaked at 30 minutes. The other five peaked somewhere between eight and twelve hours. Oral bioavailability was high, at 84.6 per cent, and the elimination half-life was 166 minutes — but the same dose in two dogs of the same breed can peak seven hours apart.

That variability is why the practical advice is boring and correct: give the first dose at home on a quiet day, write down the time, and watch. A dog that gets its trial dose on the morning of a thunderstorm forecast and its first real dose on the way to a dental appointment is a dog whose owner has learned nothing except that the drug is unpredictable.

Dosing ranges in the literature are wide, from roughly 1.7 to 19.5 mg/kg per day, usually with ceilings of 300 mg per dose and 600 mg in 24 hours, and the standard instruction to start low and titrate. A nationwide UK primary-care analysis of 2.28 million dogs in 2023 found a median as-needed dose of 7.17 mg/kg, and the single most common regimen was a dose the night before an event plus a second two hours beforehand. The peer-reviewed clinical monograph on trazodone suggests starting lower, around 2 to 3 mg/kg, precisely because individual responses vary so much.

There is no veterinary-licensed trazodone product anywhere. Every dose is extra-label, built on human tablets, and no dose-determination study has ever been run in dogs. That isn't a reason to refuse the drug. It is a reason to be honest that the numbers are borrowed.

What goes wrong, and how badly

The headline risk is serotonin syndrome, which happens when serotonin signalling runs too hot. Signs include vomiting, diarrhoea, tremors, muscle rigidity, dilated pupils, agitation, disorientation, hyperthermia, a racing heart and seizures. It can be fatal without treatment. The risk climbs when trazodone is stacked on other serotonergic drugs: selective serotonin reuptake inhibitors such as fluoxetine, tricyclics such as clomipramine and amitriptyline, tramadol, and monoamine oxidase inhibitors — a category that includes selegiline and the amitraz found in some tick collars and dips. Combining trazodone with a monoamine oxidase inhibitor is a straightforward contraindication.

Monitoring advice is surprisingly concrete. A heart rate more than 30 per cent above the dog's baseline can be an early signal, and rates above 150 beats per minute have been reported in dogs with serotonin syndrome after accidental ingestion. VCA's owner-facing guidance on serotonin syndrome covers what treatment involves: decontamination if the ingestion is recent, supportive care, and a serotonin antagonist such as cyproheptadine.

Then there's the pharmacy hazard nobody warns you about. Trazodone and tramadol look alike on a handwritten script, sound alike across a noisy counter, and both push serotonin. If your dog is prescribed both, check the label out loud.

Other signals come from the toxicology literature. The ASPCA Animal Poison Control Center logged 417 single-agent trazodone exposures in 379 dogs between 2009 and 2013; among the 104 dogs that developed signs, sedation or lethargy appeared in 43 per cent, ataxia in 16 per cent and vomiting in 14 per cent. The lowest doses at which particular signs have been reported range from 0.55 mg/kg for lethargy to 78.7 mg/kg for seizure. Liver injury has been documented in a dog receiving 4 mg/kg every 12 to 24 hours. Today's Veterinary Nurse's review of trazodone toxicology sets out the full dose-sign table.

Two newer findings deserve more attention than they've had. A single-blinded, placebo-controlled crossover study of 15 dogs published in the Journal of Veterinary Internal Medicine found that trazodone reduced platelet aggregation on one assay, while bleeding time and a second platelet-function test were unchanged, and there was no effect on cardiac rhythm or the corrected QT interval. The authors recommended caution in dogs with known or suspected impaired primary haemostasis — and flagged that nearly half their cohort were herding breeds, which carry the MDR1 mutation, though reduced aggregation showed up in both groups. The same paper is worth reading for its limitations: a conservative dose, a short course, and owners doing the dosing.

Separately, a study of 32 dogs given 6.25 to 8.60 mg/kg found seven developed new or worsened proprioceptive deficits on neurological examination, and just under a fifth shifted from bright and alert to a quieter but still responsive state. No dog became obtunded. The practical lesson is narrow but useful: if your dog needs an urgent neurological exam and has had trazodone, say so, because mild findings may not be the disease.

Nails, vaccinations and the seventy per cent problem

What is all this prescribing actually for? The UK primary-care data gives an unexpectedly domestic answer. The two most common contexts for a trazodone prescription were nail clipping, at just under 12 per cent of recorded use, and vaccination, at 11.7 per cent. Belgian Shepherds, Rottweilers and German Shepherds were over-represented compared with crossbreeds; so were neutered dogs and dogs aged two to four.

Meanwhile, in the US records study, roughly 70 per cent of dogs prescribed a psychoactive medication had no behaviour problem recorded anywhere in their notes. That's not proof of bad medicine — a code for 'nervous during exam' rarely gets typed into a practice management system — but it does mean the behavioural reason for a prescription is often invisible in the data, which makes it hard to audit.

None of this is inherently wrong. A dog that panics during nail clipping is genuinely suffering, and a dog that can't be examined is a dog whose ear infection goes untreated. Pre-visit medication has real welfare value, and surveys of North American shelters and rescues consistently find trazodone the most-used medication for dogs, particularly for situational stress. Sedation used to make a necessary procedure tolerable is a kindness.

The line worth drawing is between a drug that buys you a workable appointment and a drug that substitutes for addressing the problem. A dog who needs trazodone every time the doorbell rings still has a doorbell problem. Behaviour modification, environmental change and, where needed, a daily serotonergic medication prescribed for months rather than hours are the tools for that, and they're the ones a veterinary behaviourist is trained to combine.

Photo by Yulin Wang on Unsplash

Questions worth asking before you fill the script

Most of the useful safety work happens in a two-minute conversation at the counter, and most of it doesn't happen by default. These are the things worth asking out loud.

• Is this for a single event or daily use, and what specifically should improve?
• What's the dose in mg per kilogram, and what's my ceiling in any 24 hours?
• Is my dog on anything else that raises serotonin, including tramadol, an SSRI, or a tick collar containing amitraz?
• What does a bad reaction look like in this particular dog, and which number do I call at 10pm?
• What are we doing about the behaviour that doesn't involve a tablet?

Then do the trial run. Give the first dose on a quiet Tuesday, at home, and keep a note of the time. You'll learn more in four hours than any leaflet can tell you — whether your dog gets sleepy, whether it gets wobblier than you'd like, whether it goes the other way entirely and becomes restless and prickly. Paradoxical excitation is uncommon but real, and it is the single best argument against giving a first dose in a car park before an appointment.

And keep the pill away from the dog's regular food bowl. If the tablet goes into dinner and the dog then refuses dinner for a week, you've taught it something you can't unteach.

Cheese, for the record, still works as a delivery mechanism. Your dog will notice it anyway — dogs always notice the cheese — but at least you'll know what the tablet is doing, roughly when it will peak, and which signs mean you stop guessing and pick up the phone.